VS-7375: An Oral, Selective KRAS G12D (ON/OFF) Inhibitor with Potent Preclinical Anti- Tumor Efficacy & Promising Initial Clinical Data
- Characterization as a selective KRAS G12D (ON/OFF) inhibitor and differentiation vs. other RAS inhibitors
- Exploring combinations in preclinical models to define clinical directions
- Clinical update